Fungal infections in transplant recipients receiving alemtuzumab

Transplantation Proceedings

Volumn 37, Issue 2, 2005, Pages 934-936

  Nath, D S ^a   Kandaswamy, R ^a   Gruessner, R ^a   Sutherland, D E R ^a   Dunn, D L ^a   Humar, A ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CAPSOFUNGIN; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PENICILLIN G; UNCLASSIFIED DRUG; VORICONAZOLE;

ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CONFERENCE PAPER; CRYPTOCOCCOSIS; CRYPTOCOCCUS; FUNGAL MENINGITIS; FUNGEMIA; FUNGUS CULTURE; FUNGUS IDENTIFICATION; HEART INFARCTION; HISTOPATHOLOGY; HISTOPLASMA; HISTOPLASMOSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYCOSIS; NONHUMAN; PANCREAS TRANSPLANTATION; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; URINARY TRACT INFECTION;

EID: 17844379257     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2005.01.054     Document Type: Conference Paper

References (12)

1. L. Reichman, M. Clark, H. Waldmann Reshaping human antibodies for therapy Nature 332 1998 323
2. J.R. Salisbury, N.T. Rapson, J.D. Codd Immunohistochemical analysis of CD 52 antigen expression in non-Hodgkin's lymphomas J Clin Pathol 47 1994 313
3. M.H. Gilleece, T.M. Dexter Effect of Campath I-H antibody on human hematopoietic progenitors in vitro Blood 82 1993 807
4. A. Tzakis, T. Kato, S. Nishida Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation Transplantation 75 2003 1512
5. R. Calne, P. Friend, S. Moffatt Prope tolerance, perioperative Campath-1H, and low-dose cylosporine monotherapy in renal allograft recipients Lancet 351 1998 1701
6. S.J. Knechtle Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients Pediatr Transplantation 8 2004 106
7. K.R. Rai, C.E. Freter, R.J. Mercier Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine J Clin Onco 20 2002 3891
8. J. Lundin, H. Hagberg, R. Repp Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome Blood 101 2003 4267
9. P.J. Friend, H. Waldmann, G. Hale Reversal of allograft rejection using the monoclonal antibody, Campath-1G Transplant Proc 23 1991 2253
10. R. Calne, S.D. Moffatt, P.J. Friend Campath 1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients Transplantation 68 1999 1613
11. D.G. Farmer, S.V. McDiarmid, H. Yersiz Outcome after intestinal transplantation: results from one center's 9-year experience Arch Surg 136 2001 1027
12. I.M. Ghobrial, L.A. Otteman, W.I. White An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab N Engl J Med 349 2003 2570